Vincenza Calvaruso Selected Research

PAcein

1/2015	Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis.
1/2015	Comparison of Histochemical Staining Methods and Correlation with Transient Elastography in Acute Hepatitis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Vincenza Calvaruso Research Topics

Disease

35	Fibrosis (Cirrhosis) 04/2021 - 10/2007
8	Liver Cirrhosis (Hepatic Cirrhosis) 01/2022 - 02/2010
8	Chronic Hepatitis C 10/2021 - 11/2006
7	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 10/2008
7	Liver Diseases (Liver Disease) 01/2021 - 08/2009
6	Infections 01/2022 - 05/2012
6	Chronic Hepatitis (Chronic Active Hepatitis) 06/2016 - 11/2006
5	Hepatitis 01/2015 - 04/2011
2	Non-alcoholic Fatty Liver Disease 10/2021 - 05/2011
2	Type 2 Diabetes Mellitus (MODY) 12/2020 - 01/2013
2	Hypertension (High Blood Pressure) 01/2020 - 01/2013
2	beta-Thalassemia (Cooley's Anemia) 06/2016 - 05/2012
2	Chronic Hepatitis B 08/2013 - 04/2011
2	Inflammation (Inflammations) 07/2012 - 05/2011
2	Portal Hypertension 07/2012 - 10/2007
1	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 04/2021
1	Virus Diseases (Viral Diseases) 12/2020
1	Atherosclerosis 11/2020
1	Hemorrhage 01/2019
1	Hepatitis C 01/2018
1	Carotid Artery Diseases 01/2018
1	Liver Neoplasms (Liver Cancer) 01/2017
1	Liver Failure 01/2017
1	Varicose Veins (Varicose Vein) 12/2016
1	Disease Progression 12/2016
1	Diarrhea 07/2012
1	Thalassemia 05/2012
1	Persistent Infection 05/2012
1	Fatty Liver 12/2011
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 05/2011
1	Critical Illness (Critically Ill) 08/2010
1	Hypoxia (Hypoxemia) 10/2008
1	Neoplasms (Cancer) 10/2008
1	Body Weight (Weight, Body) 11/2006

Drug/Important Bio-Agent (IBA)

24	Antiviral Agents (Antivirals)IBA 01/2022 - 10/2007
11	InterferonsIBA 12/2016 - 11/2006
9	Ribavirin (Virazole)FDA LinkGeneric 01/2018 - 11/2006
4	4- (4- dihexadecylaminostyryl)- N- methylpyridium (DiA)IBA 01/2015 - 04/2009
4	CollagenIBA 01/2015 - 07/2012
3	Biomarkers (Surrogate Marker)IBA 06/2019 - 07/2012
2	Pharmaceutical PreparationsIBA 04/2021 - 05/2012
2	daclatasvirIBA 01/2019 - 01/2018
2	PAceinIBA 01/2015 - 01/2015
2	CreatinineIBA 01/2013 - 01/2011
2	IronIBA 05/2012 - 02/2010
2	Alanine Transaminase (SGPT)IBA 12/2011 - 08/2009
1	elbasvirIBA 01/2022
1	grazoprevirIBA 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	Bevacizumab (Avastin)FDA Link 01/2022
1	atezolizumabIBA 01/2022
1	Ursodeoxycholic Acid (Urso)FDA LinkGeneric 04/2021
1	obeticholic acidIBA 04/2021
1	SuspensionsIBA 04/2021
1	F2-Isoprostanes (F2 Isoprostanes)IBA 11/2020
1	CholesterolIBA 01/2020
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2020
1	Aminopyrine (Aminophenazone)IBA 01/2020
1	SofosbuvirIBA 01/2018
1	Estradiol (Delestrogen)FDA LinkGeneric 09/2015
1	TransferasesIBA 09/2014
1	DNA (Deoxyribonucleic Acid)IBA 02/2014
1	RNA (Ribonucleic Acid)IBA 01/2014
1	telaprevirIBA 01/2014
1	Protease Inhibitors (Protease Inhibitor)IBA 01/2014
1	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA 01/2014
1	Azathioprine (Imuran)FDA LinkGeneric 05/2013
1	Leukocyte L1 Antigen Complex (Calgranulin)IBA 07/2012
1	4-(3-chlorophenylsulfanyl)piperidineIBA 07/2012
1	Ferritins (Ferritin)IBA 05/2011
1	Cystatin CIBA 01/2011
1	SodiumIBA 08/2010
1	EnzymesIBA 08/2009
1	Angiogenesis InhibitorsIBA 10/2008

Therapy/Procedure

18	Therapeutics 01/2022 - 10/2007
5	Liver Transplantation 01/2018 - 01/2011
1	Transjugular Intrahepatic Portasystemic Shunt 01/2019
1	Surgical Portasystemic Shunt (Portosystemic Shunt) 01/2019
1	Retreatment 01/2017
1	Transplantation 08/2013